PDL BioPharma, Inc. (PDLI): Price and Financial Metrics


PDL BioPharma, Inc. (PDLI): $2.47

-0.23 (-8.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PDLI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PDLI Stock Price Chart Interactive Chart >

Price chart for PDLI

PDLI Price/Volume Stats

Current price $2.47 52-week high $3.86
Prev. close $2.70 52-week low $2.09
Day low $2.39 Volume 30,270,700
Day high $2.78 Avg. volume 1,480,534
50-day MA $2.42 Dividend yield N/A
200-day MA $2.92 Market Cap 282.14M

PDL BioPharma, Inc. (PDLI) Company Bio


PDL BioPharma Inc. manages a portfolio of patents and royalty assets related to the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. The company was founded in 1986 and is based in Incline Village, Nevada.


PDLI Latest News Stream


Event/Time News Detail
Loading, please wait...

PDLI Latest Social Stream


Loading social stream, please wait...

View Full PDLI Social Stream

Latest PDLI News From Around the Web

Below are the latest news stories about Pdl Biopharma Inc that investors may wish to consider to help them evaluate PDLI as an investment opportunity.

Silver Point Capital L.P. Acquires 640,000 Shares of PDL BioPharma, Inc. (NASDAQ:PDLI) Stock

PDL BioPharma, Inc. (NASDAQ:PDLI) major shareholder Silver Point Capital L.P. bought 640,000 shares of the firm’s stock in a transaction that occurred on Monday, December 14th. The stock was purchased at an average cost of $2.62 per share, with a total value of $1,676,800.00. The acquisition was disclosed in a filing with the Securities & […]

Watchlist News | December 16, 2020

Is PDLI A Good Stock To Buy Now?

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks aren’t doing […]

Yahoo | December 16, 2020

PDL BioPharma enters Capital Provision Agreement with Epps Investments

PDL BioPharma ([[PDLI]] +5.2%) has entered into a Capital Provision Agreement with Epps Investments LLC. Under the terms, Epps to pay PDL ~$51.39M no later than December 31, 2020, in exchange for 100% of the payments received by PDL on or after the date of the Agreement pursuant to the...

Seeking Alpha | December 14, 2020

PDL BioPharma Enters into $51.4 Million Capital Provision Agreement with Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement with Wellstat

PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps Investments LLC ("Epps"). Under the terms of the Agreement, Epps will pay PDL $51,391,184 no later than December 31, 2020, in exchange for 100% of the payments or other property or value received by PDL on or after the date of the Agreement pursuant to the settlement agreement (the "Settlement Agreement") with related entities of Defined Diagnostics, LLC (f/k/a Wellstat Diagnostics, LLC) ("Wellstat Diagnostics") announced August 12, 2020, and the underlying claims resolved by the Settlement Agreement. The Settlement Agreement resolved previously reported litigation relating to loans made to Wellstat Diagnostics by PDL. PDL has agreed to ...

Yahoo | December 14, 2020

PDL Announces Timeline for Voluntarily Delisting from Nasdaq

INCLINE VILLAGE, Nev., Dec. 8, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has formally notified The Nasdaq Stock Market, Inc. of its intent to delist the Company's common stock from the Nasdaq Global Select Market ("Nasdaq")….

PR Newswire | December 8, 2020

Read More 'PDLI' Stories Here

PDLI Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -15.41%
5-year 3.35%
YTD N/A
2021 N/A
2020 0.00%
2019 11.90%
2018 5.84%
2017 29.25%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0765 seconds.